A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02381886 |
Recruitment Status :
Active, not recruiting
First Posted : March 6, 2015
Last Update Posted : February 28, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Malignancies That Harbor IDHR132 Mutations | Drug: IDH305 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 166 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations |
Actual Study Start Date : | January 6, 2015 |
Actual Primary Completion Date : | December 7, 2016 |
Estimated Study Completion Date : | October 24, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: IDH305 |
Drug: IDH305 |
- Incident rate of dose limiting toxicities (DLTs) [ Time Frame: 21 days ]To estimate the maximum tolerated dose/recommended dose for expansion (MTD/RDE)
- Incidence of adverse events (AEs) [ Time Frame: 30 months ]To characterize the safety and tolerability of IDH305
- Plasma PK parameters (AUC, Cmax, Tmax) [ Time Frame: 30 months ]To characterize the PK profile of IDH305
- Changes of 2-hydroxyglutarate concentration in patient specimens [ Time Frame: 30 months ]To characterize the PD profile of IDH305
- Overall response rate (ORR) [ Time Frame: 30 months ]To assess any preliminary anti-tumor activity of IDH305
- Incidence of serious adverse events (SAE) [ Time Frame: 30 months ]To characterize the safety and tolerability of IDH305
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Documented IDH1R132-mutant tumors
- ECOG performance status ≤ 2
Exclusion Criteria:
- Patients who have received prior treatment with a mutant-specific IDH1 inhibitor (with the exception of glioma patients)
- Medical conditions that would prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures such as the presence of other clinically significant cardiac, respiratory, gastrointestinal, renal, hepatic or neurological disease.
- Acute Promyelocytic Leukemia
- Women who are pregnant or lactating
Other protocol-defined Inclusion/Exclusion may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02381886
United States, Massachusetts | |
Dana Farber Cancer Institute SC (1) | |
Boston, Massachusetts, United States, 02115 | |
United States, New York | |
Columbia University Medical Center- New York Presbyterian Onc Dept. | |
New York, New York, United States, 10032 | |
United States, Texas | |
Uni of TX MD Anderson Cancer Cntr . | |
Houston, Texas, United States, 77030 | |
Australia, Victoria | |
Novartis Investigative Site | |
Melbourne, Victoria, Australia, 3004 | |
Novartis Investigative Site | |
Parkville, Victoria, Australia, 3050 | |
Belgium | |
Novartis Investigative Site | |
Leuven, Belgium, 3000 | |
Canada, Ontario | |
Novartis Investigative Site | |
Toronto, Ontario, Canada, M5G 2M9 | |
Germany | |
Novartis Investigative Site | |
Heidelberg, Germany, 69120 | |
Novartis Investigative Site | |
Jena, Germany, 07740 | |
Novartis Investigative Site | |
Koeln, Germany, 50937 | |
Netherlands | |
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55 | |
Rotterdam, Netherlands, 3075 EA | |
Singapore | |
Novartis Investigative Site | |
Singapore, Singapore, 168583 | |
Spain | |
Novartis Investigative Site | |
Barcelona, Catalunya, Spain, 08035 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02381886 |
Other Study ID Numbers: |
CIDH305X2101 |
First Posted: | March 6, 2015 Key Record Dates |
Last Update Posted: | February 28, 2024 |
Last Verified: | February 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
IDHR132 mutations IDH305 IDH IDH1 AML Acute Myeloid Leukemia Leukemia Myeloid Acute |
MDS Myelodysplastic Syndrome Glioma Oligodendroglioma Astrocytoma Glioblastoma Cholangiocarcinoma Solid Tumors |
Neoplasms |